Tagged with Manufacturing

Egypt Egypt’s largest pharmaceutical manufacturer by units, EIPICO, plans to diversify its production capacity by building the country’s first biological & biosimilar production plant. Not only that, the company is leading the change towards localization and local production of APIs. Founded in 1980, EIPICO is currently the number one company in…

Egypt The chairman of EIPICO – Egypt’s largest pharma company by units –, Dr Ahmed Kelani, outlines the company’s ambitious growth strategy, which includes the construction of the first biological & biosimilar production plant in Egypt. The plant is expected to commence production at the end of 2023 and would become…

South Korea South Korea has carved a place for itself as a dominant player in the global pharma and med-tech manufacturing industry with national companies Samsung Biologics and Celltrion leading the way. In 2019, the South Korean government announced a USD 1.7 billion five-year plan to fund biotech-related projects with the intention…

Africa David Mukanga of the Bill and Melinda Gates Foundation gives an overview of the latest developments on the long road towards the creation of an African Medicines Agency and the push to establish vaccine manufacturing facilities on the continent.   Since the minimum number of 15 ratifications by African Union…

Global The Contract Development and Manufacturing Organisation (CDMO) industry has boomed in recent years, with Big Pharma increasingly focusing on its core business of R&D and outsourcing other elements of the supply chain, including manufacturing, to third-party CDMOs. Additionally, the global proliferation of biotechs – most of which lack the in-house…

China Some of the most significant recent stories emanating from Chinese healthcare and life sciences, including why the development of a domestic mRNA COVID vaccine – widely acknowledged as an essential tool to shifting away from the country’s zero-COVID policy – is under threat from new mutations of the virus. Other…

Korea After a dynamic two years as CEO of Samsung Biologics, John Rim highlights some of the fundamentals behind the company’s rapid growth as a CDMO, including the creation of huge new manufacturing facilities to cope with increased demand, a dedication to carrying out technology transfers at half the speed of…

WHO Representatives from the US FDA, EMA, WHO and the pharma industry debated over the possible inclusion of environmental impact in future good manufacturing practice (GMP) inspections of drug production sites and the need for a new type of relationship between companies and regulators. We need more information and data to…

Europe The new president of Medicines for Europe, Elisabeth Stampa, outlines one of the priorities of her mandate: working to adjust the EU pharma policy framework to improve access for patients across Europe.    Regulatory flexibilities implemented during COVID-19 showed that the EU system can require one of highest safety, quality…

Europe When the COVID-19 pandemic struck in early 2020, Europe’s reliance on active pharmaceutical ingredient (API) and generic medicine suppliers outside of the continent was laid bare. In the face of crisis, countries like India and China understandably looked first to safeguard their own populations which, combined with supply chain strains…

India The latest healthcare and pharma news from India, including the opening up of COVID-19 vaccine booster shots to all adults; the lowering of vaccine prices; and the licences granted to 19 Indian pharmaceutical firms for the generic version of Pfizer’s oral antiviral COVID-19 pill.   COVID-19 vaccine booster shots now…

Global Antimicrobial pollution is a major global health and environmental risk. Shawview Consulting’s Brendan Shaw and Nicolai Schaaf of SIWI uncover what antibiotics manufacturers are doing about it.   Last month, global leaders issued an urgent call for all countries to reduce antimicrobial pollution. This includes the safe disposal of antimicrobial…